917565-58-3

Upstream product

• 917565-57-2 4-[(2S,3R)-3-[(3S)-3-(acetyloxy)-3-(4-fluorophenyl)propyl]-1-(4-{3-[(methylsulfonyl)amino]prop-1-yn-1-yl}phenyl)-4-oxoazetidin-2-yl]phenyl acetate 
• 917565-48-1 4-[(2S,3R)-3-[(3S)-3-(acetyloxy)-3-(4-fluorophenyl)propyl]-1-(4-iodophenyl)-4-oxoazetidin-2-yl]phenyl acetate 
• 190448-59-0 (1S)-1-(4-fluorophenyl)-3-[(2S,3R)-2-(4-hydroxyphenyl)-1-(4-iodophenyl)-4-oxoazetidin-3-yl]propyl acetate 

Downstream Products

• 1039433-06-1 C₃₀H₃₃FN₂O₆S 
• 917565-60-7 C₆₆H₆₇FN₂O₁₀S 
• 917565-59-4 (1S)-1-(4-fluorophenyl)-3-[(3R,4S)-1-(4-{3-[(methylsulfonyl)amino]propyl}phenyl)-2-oxo-4-(4-{[(trifluoromethyl)-sulfonyl]oxy}phenyl)azetidin-3-yl]propyl acetate 

Relevant academic research and scientific papers

ANTI-HYPERCHOLESTEROLEMIC COMPOUNDS

One object of the instant invention is to provide novel cholesterol absorption inhibitors of Formula I or pharmaceutically acceptable salts thereof.

ANTI-HYPERCHOLESTEROLEMIC COMPOUND

This invention provides a novel crystalline form of N-[3-(4-{(2S,3R)-2-{4-[3,4-dihydroxy-3-(hydroxymethyl)butyl]phenyl}-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-1-yl}phen yl)propyl]methanesulfonamide. The compound is useful for lowering p

Anti-hypercholesterolemic compounds

This invention provides cholesterol absorption inhibitors of Formula I: and the pharmaceutically acceptable salts and esters thereof. The compounds are useful for lowering plasma cholesterol levels, particularly LDL cholesterol, and for treating and preventing atherosclerosis and atherosclerotic disease events.

ANTI-HYPERCHOLESTEROLEMIC COMPOUNDS

This invention provides cholesterol absorption inhibitors of Formula (I), and the pharmaceutically acceptable salts and esters thereof. The compounds are useful for lowering plasma cholesterol levels, particularly LDL cholesterol, and for treating and preventing atherosclerosis and atherosclerotic disease events.